Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Eyepoint Pharmaceuticals Inc (EYPT)

Eyepoint Pharmaceuticals Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference GlobeNewswire - Tue Dec 17, 6:00AM CST

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Mon Dec 16, 6:00AM CST

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUCIA Trial for DURAVYU in Wet AMD Quiver Quantitative, Inc. - Wed Dec 4, 4:16PM CST

EyePoint Pharmaceuticals initiates LUCIA trial for DURAVYU, evaluating efficacy in wet AMD with data expected in 2026.Quiver AI SummaryEyePoint Pharmaceuticals announced that the first patient has been...

EYPT : 7.33 (+1.10%)
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration GlobeNewswire - Wed Dec 4, 6:00AM CST

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Mon Nov 18, 6:00AM CST

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals: Q3 Earnings Snapshot AP - Thu Nov 7, 6:37AM CST

EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments GlobeNewswire - Thu Nov 7, 6:00AM CST

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences GlobeNewswire - Mon Nov 4, 6:00AM CST

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire - Thu Oct 31, 3:00PM CDT

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering GlobeNewswire - Tue Oct 29, 8:47PM CDT

EYPT : 7.33 (+1.10%)

Barchart Exclusives

Elon Musk's Critical Advice For Growing a Billion Dollar Business: Stop Focusing on Competitors 'It’s Sort of Like the Old Adage of Running' Barchart - 22 minutes ago
In a world where businesses obsess over competitive landscapes, Tesla (TSLA) and SpaceX CEO Elon Musk shared a contrarian stance that might actually go against the grain in the world of marketing and growing a business. “I’m not sure looking at competitors really helps. It’s sort of like the old... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot